Join the Calquence group to help and get support from people like you.
Calquence News
Acalabrutinib-Venetoclax Prolongs Survival in Previously Untreated Leukemia
FRIDAY, Feb. 21, 2025 – For patients with previously untreated chronic lymphocytic leukemia (CLL), fixed-duration acalabrutinib-venetoclax with or without obinutuzumab significantly prolongs...
Calquence Plus Chemoimmunotherapy Approved in the U.S. for Patients with Previously Untreated Mantle Cell Lymphoma
17 January 2025 – AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated m...
Calquence Tablet Formulation Approved in the US Across Current indications
New formulation can be co-administered with gastric acid-reducing agents Tablet offers equivalent efficacy, safety and consistent dosing compared to current capsule 5 August 2022 – AstraZeneca’s n...
FDA Approves Calquence for Adults with Chronic Lymphocytic Leukemia
21 November 2019 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukemia (CLL) or s...
FDA Approves Calquence (acalabrutinib) for Adults with Mantle Cell Lymphoma
October 31, 2017 – The U.S. Food and Drug Administration today granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at...
Further information
Related condition support groups
Chronic Lymphocytic Leukemia (CLL)